Numéro
Therapie
Volume 70, Numéro 2, Mars-Avril 2015
Addictovigilance : le défi pharmacologique de l'évaluation et de la prévention des substances à risque
Page(s) 229 - 234
Section Addictovigilance / Addictovigilance
DOI https://doi.org/10.2515/therapie/2015016
Publié en ligne 9 avril 2015
  1. Whelan PJ, Remski K. Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract 2012 Jan; 3(1): 45-50 [CrossRef] [PubMed] [Google Scholar]
  2. World Health Organization. Atlas on substance use: resources for the prevention and treatment of substance use disorders. Chapter 3: Substance-related disorders - prevention and control 2010. ISBN: 978 92 4 150061 6 http://www.who.int/substance_abuse/publications/treatment/en/ Accessed February 9th, 2015 [Google Scholar]
  3. College of Physicians and Surgeons of Ontario. Methadone Maintenance Treatment for Opioid Dependence. Dialogue, Issue 2. Policy Statement #2–10. Toronto 2010. http://www.cpso.on.ca/uploadedFiles/policies/policies/policyitems/methadone_maintenance.pdf Accessed February 9th, 2015 (8 pages) [Google Scholar]
  4. Dasgupta N, Davis J, Jonsson Funk M, et al. Using poison center exposure calls to predict methadone poisoning deaths. PLoS One 2012; 7: e41181 [CrossRef] [PubMed] [Google Scholar]
  5. Haute Autorité de Santé. Methadone opinion of transparency committee. Paris 2007. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-06/methadone_ap-hp_ct_5198.pdf Accessed February 9th, 2015 (6 pages) [Google Scholar]
  6. Nosyk B, Marsh DC, Sun H, et al. Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. J Subst Abuse Treat 2010 Jul; 39(1): 22-31 [CrossRef] [PubMed] [Google Scholar]
  7. Royal College of General Practitioners. Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care. London 2011. http://www.rcgp.org.uk/revalidation-and-cpd/~/media/Files/SMAH/RCGP-Guidance-for-the-use-of-substitute-prescribing-in-the-treatment-of-opioid-dependence-in-primary-care-2011.ashx Accessed February 9th, 2015 (48 pages) [Google Scholar]
  8. Société Scientifique des Pharmaciens Francophones. La méthadone : bien prescrire, bien délivrer. E-news médecin-pharmacien 2009 http://sspf.claroline.com/claroline/backends/download.php?url=L2VuZXdzXzIwMDkvbel0aGFkb25lX19wcmVzY3JpcmVfZXRfZOlsaXZyZXIucGRm&cidReset=true&cidReq=NEWS Accessed February 9th, 2015 (2 pages) [Google Scholar]
  9. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report. Lisbon 2013. ISSN 1977-9887 http://www.ofdt.fr/BDD/publications/docs/edr2013rap.pdf Accessed February 9th, 2015 (80 pages) [Google Scholar]
  10. Riksheim M, Gossop M, Clausen T. From methadone to buprenorphine: changes during a 10 year period within a national opioid maintenance treatment programme. J Subst Abuse Treat 2014 Mar; 46(3): 291-4 [CrossRef] [PubMed] [Google Scholar]
  11. Commission Nationale des Stupéfiants et des Psychotropes. Compte-rendu de la séance du 21 octobre 2014. Paris http://ansm.sante.fr/var/ansm_site/storage/original/application/b6fa9fda146dc1ba87818c4f3e215e0e.pdf Accessed February 9th, 2015 (14 pages) [Google Scholar]
  12. Dupouy J, Dassieu L, Bourrel R, et al. Effectiveness of drug tests in outpatients starting opioid substitution therapy. J Subst Abuse Treat 2013; 44: 515-21 [CrossRef] [PubMed] [Google Scholar]
  13. Agence Nationale d’Accréditation et d’Évaluation en Santé. Conférence de consensus stratégies thérapeutiques pour les personnes dépendantes des opiacés : place des traitements de substitution. Paris. 2004 http://www.has-sante.fr/portail/upload/docs/application/pdf/TSO_court.pdf Accessed February 9th, 2015 (16 pages) [Google Scholar]
  14. Brondani M, Park P E. Methadone and oral health--a brief review. J Dent Hyg 2011; Spring; 85(2): 92-8 [PubMed] [Google Scholar]
  15. Mysels DJ, Vosburg SK, Benga I, et al. Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients. J Opioid Manag 2011 Jan-Feb; 7(1): 47-53 [CrossRef] [PubMed] [Google Scholar]
  16. Commission Nationale des Stupéfiants et des Psychotropes. Méthadone gélule : rapport étude observationnelle + bilan à 2 ans de commercialisation. Addendum au compte rendu du 29 avril 2010. http://ansm.sante.fr/var/ansm_site/storage/original/application/14f894f589f68d73eb7217ac3bdc39d3.pdf Accessed February 9th, 2015 (13 pages) [Google Scholar]
  17. Tuppin P, Neumann A, Danchin N, et al. Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. Arch Cardiovasc Dis 2009 Apr; 102(4): 279-92 [CrossRef] [PubMed] [Google Scholar]
  18. Ameli. Health reimbursed national system: data on reimbursed drug from 2008 to 2011. Paris, 2012 http://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/donnees-statistiques/medicament/medic-am-2008-2012.php Accessed February 9th, 2015 [Google Scholar]
  19. European Monitoring Centre for Drugs and Drug Addiction. National Report 2012 (2011 data) to the EMCDDA by the Reitox National Focal Point France. New Development, Trends and in-depth information on selected issues. http://www.emcdda.europa.eu/...cfm/att_213784_EN_Austria_NR2012.pdf Accessed February 9th, 2015 (236 pages) [Google Scholar]
  20. Eiden C, Léglise Y, Bertomeu L, et al. New formulation of methadone for opioid dependence in France: acceptability and diversion/misuse liability. Therapie 2013 Mar-Apr; 68(2): 107-11 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  21. Eiroa-Orosa FJ, Haasen C, Verthein U, et al. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend 2010 Dec 1; 112(3): 226-33 [CrossRef] [PubMed] [Google Scholar]
  22. Peles E, Schreiber S, Naumovsky Y, et al. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord 2007 Apr; 99(1-3): 213-20 [CrossRef] [PubMed] [Google Scholar]
  23. Teesson M, Havard A, Fairbairn S, et al. Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend 2005 Jun 1; 78(3): 309-15 [CrossRef] [PubMed] [Google Scholar]
  24. Bramness JG, Kornør H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007 Oct 8; 90(2-3): 203-9 [CrossRef] [PubMed] [Google Scholar]
  25. Lee HY, Li JH, Wu LT, et al. Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst Abuse Treat Prev Policy 2012 Mar 20 ; 7: 11 [CrossRef] [PubMed] [Google Scholar]
  26. Pradel V, Delga C, Rouby F, et al. Assessment of abuse potential of benzodiazepines from a prescription database using “doctor shopping” as an indicator. CNS Drugs 2010; 24: 611-20 [CrossRef] [PubMed] [Google Scholar]
  27. Nordmann S, Pradel V, Lapeyre-Mestre M, et al. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician 2013; 16: 89-100 [PubMed] [Google Scholar]
  28. Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Medicine 2010; 11: 1078-91 [CrossRef] [PubMed] [Google Scholar]
  29. Commission Nationale des Stupéfiants et des Psychotropes. Compte-rendu de la séance du 20 mars 2014. Paris, 2014 http://ansm.sante.fr/var/ansm_site/storage/original/application/125636cafe5929ba7f654eb148fc5c07.pdf Accessed February 9th, 2015 (24 pages) [Google Scholar]
  30. Frauger E, Nordmann S, Orleans V, et al. Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey. Fundam Clin Pharmacol 2012 Aug; 26(4): 549-56 [CrossRef] [PubMed] [Google Scholar]